COPD - Nationale VersorgungsLeitlinien

103. Mulloy E,McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in
severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;148(4 Pt 1):1030-6.
104. Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength
and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984;311(6):349-
53.
105. Williamson BH, Milligan C, Griffith K, Sparta S, Triebe AC, Thompson PJ. An assessment of major
and minor side effects of theophylline. Aust N Z J Med 1988;19:539.
106. Kirsten DK, Wegner RE, Jorres RA, Magnussen H. Effects of theophylline withdrawal in severe
chronic obstructive pulmonary disease. Chest 1993;104(4):1101-7.
107. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The
COMBIVENT Inhalation Solution Study Group. Chest 1997;112(6):1514-21.
108. Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG. The efficacy of orally administered
theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the
management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis
1985;131(5):747-51.
109. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J. In
patients with COPD, treatment with a combination of formoterol and ipratropium is more effective
than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, withinpatient,
multicenter study. Chest 2001;119(5):1347-56.
110. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of
chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur
Respir J 2000;15(5):878-85.
111. Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, Kuskowski M, Joseph AM, Niewoehner DE.
Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J
Respir Crit Care Med 2000;162(1):174-8.
112. Senderovitz T, Vestbo J, Frandsen J, Maltbaek N, Norgaard M, Nielsen C, Kampmann JP. Steroid
reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic
obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med
1999;93(10):715-8.
113. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in
chronic airflow obstruction. Am J Respir Crit Care Med 1994;150(1):11-6.
114. Decramer M,Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with
chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 1992;146(3):800-2.
115. Schols AM, Wesseling G, Kester AD, de Vries G, Mostert R, Slangen J, Wouters EF. Dose
dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J
2001;17(3):337-42.
116. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist
in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2004;(3):CD003794.
117. Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM. N-acetylcysteine reduces the
exacerbation rate in patients with moderate to severe COPD. Respiration 1999;66(6):495-500.
118. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, Gunnersen G, Garsdal P,
Sander P, Pedersen JZ. Orally administered N-acetylcysteine may improve general well-being in
patients with mild chronic bronchitis. Respir Med 1994;88(7):531-5.
85
© 2006